StockData

MannKind vs OPKO Health

MNKD and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MNKD and OPK compare

MannKind and OPKO Health are about the same size, with market caps of $1.3B and $1.2B.

MannKind grew revenue faster over the last twelve months (30.5% versus −11.5% for OPKO Health).

MannKind keeps more of each dollar of sales as profit, with a net margin of −11.1% compared with −12.4% at OPKO Health.

OPKO Health scores higher on the StockData Score (9 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMNKDOPK
Size and price
Market cap$1.3B$1.2B
Share price$3.96$1.62
Change, 1 year−22.0%26.6%
Change, 5 years−14.6%−60.8%
Beta (5Y)2.020.36
Employees2412,275
StockData Score
Total score69 (better)
Valuation score11
Growth score2 (better)1
Performance score23 (better)
Health score14 (better)
Dividend score00
Valuation
P/S3.2×2.1× (better)
P/B–1.0×
EV/EBITDA38.6×22.0× (better)
FCF yield−1.4% (better)−11.1%
Fair value$1.80$1.55
Margin of safety−120%−4.8% (better)
Growth
Revenue growth (TTM)30.5% (better)−11.5%
Revenue growth, 5Y average39.9% (better)−15.8%
Net income growth (TTM)−233%–
EPS growth (TTM)−218%–
Profitability
Gross margin89.8% (better)40.8%
Operating margin2.3% (better)−8.2%
Net margin−11.1% (better)−12.4%
FCF margin−4.6% (better)−22.8%
Return on equity–−5.9%
Return on invested capital–−4.0%
Financial health
Debt / equity–0.00
Net debt / EBITDA–−7.19
Interest coverage0.3×–
Current ratio1.723.35 (better)
Altman Z-score−4.48−0.21 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–3.9%
Shareholder yield0.00%3.9% (better)
Ownership
Held by institutions56.7%27.2%
Held by insiders2.5%43.6%
Insider net buying, 12 months−$2.9M−$13.2K (better)
Short interest, % of float8.4%7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.